A Phase II Trial of PET-Directed Therapy Using AVD (Doxorubicin, Vinblastine, and Dacarbazine) Plus Brentuximab Vedotin Induction Chemotherapy, With or Without Brentuximab Vedotin Plus Nivolumab, Followed by Nivolumab Consolidation for Patients With Previously Untreated Non-Bulky Limited Stage Hodgkin Lymphoma
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 16 Oct 2018
At a glance
- Drugs Nivolumab (Primary) ; Brentuximab vedotin; Dacarbazine; Doxorubicin; Vinblastine
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 30 Apr 2018 Planned number of patients changed from 85 to 82.
- 30 Apr 2018 Planned End Date changed from 1 Aug 2025 to 7 Aug 2024.